greeksoup/ stock research

SBC Medical Group Holdings (SBC) Q2 FY2026 earnings: revenue $49 million, up 13.4% on the year

SBC Medical Group Holdings Inc. (SBC) reported revenue of $49 million for Q2 FY2026, the quarter ended 30 June 2026, up 13.4% on the same quarter a year earlier. Net income was $11 million, up 335.0% on the year, and diluted earnings per share $0.10. The figures are the company's own, from the 10-Q it filed with the SEC on 13 August 2026.

Revenue$49 millionup 13.4%
Net income$11 millionup 335.0%
Diluted EPS$0.10
QuarterQ2 FY2026ended 30 June 2026

The quarter, against the one before and a year earlier

LineQ2 FY2026Q1 FY2026Q2 FY2025Change on the year
Revenue49.243.143.4+13.4%
Cost of revenue13.212.713.3-1.0%
Gross profit36.030.330.0+19.9%
Gross margin73.1%70.5%69.2%
Selling, general and administrative17.012.615.5+10.1%
Operating income19.017.714.6+30.3%
Operating margin38.5%41.2%33.6%
Interest expense0.10.10.0+170.2%
Pre-tax income19.618.913.5+44.4%
Income tax7.87.511.1-29.5%
Effective tax rate40.0%39.9%82.0%
Net income10.711.32.5+335.0%
Net margin21.7%26.3%5.7%
Diluted EPS$0.10$0.11$0.02+400.0%
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ2 FY2026Q1 FY2026Q2 FY2025Change on the year
Operating cash flow22.59.2-8.3n/a
Capital expenditure0.10.10.3-72.5%
Free cash flow22.49.1-8.6n/a
Free cash flow margin45.6%21.1%-19.9%
Cash from investing0.6-0.516.4-96.5%
Cash from financing-2.0-1.87.2n/a
Depreciation and amortisation1.10.70.6+82.4%
Diluted shares, weighted103m103m104m-0.9%
Shares outstanding at period end103m103m103m-0.5%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ2 FY2026Q1 FY2026Q2 FY2025Change on the year
Shareholders' equity264255245+7.9%
Non-controlling interest16.115.00.1+26441.4%
Debt37.840.410.4+264.0%
Operating lease liabilities4.95.71.2+305.2%
Finance lease liabilities0.10.10.2-53.2%
Other liabilities84.071.458.9+42.6%
Total liabilities and equity407388315+29.0%
Fixed assets7.47.38.1-8.0%
Goodwill15.215.45.0+202.9%
Intangible assets45.747.21.6+2783.3%
Investments1.61.5n/an/a
Cash and equivalents184167153+20.7%
Inventory3.02.31.7+74.7%
Other assets149147146+2.3%
Total assets407388315+29.0%

Questions

What was SBC Medical Group Holdings' revenue in Q2 FY2026?

SBC Medical Group Holdings (SBC) reported revenue of $49 million for Q2 FY2026, the quarter ended 30 June 2026, up 13.4% on the same quarter a year earlier.

How much did SBC Medical Group Holdings earn in Q2 FY2026?

Net income for Q2 FY2026 was $11 million, up 335.0% on the year, and diluted earnings per share $0.10.

When did SBC Medical Group Holdings report Q2 FY2026 results?

SBC Medical Group Holdings filed its 10-Q for the quarter ended 30 June 2026 with the SEC on 13 August 2026.

Quarterly results, the last 11 quarters

Q3 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue47.354.853.153.144.447.343.443.439.643.149.2
Cost of revenue13.815.313.79.810.59.613.312.710.612.713.2
Gross profit33.539.539.443.233.937.730.030.628.930.336.0
Gross margin71%72%74%81%76%80%69%71%73%70%73%
SG&A13.415.112.116.613.913.515.514.716.112.617.0
Operating income20.024.527.313.84.724.214.615.912.817.719.0
Operating margin42%45%51%26%11%51%34%37%32%41%39%
Interest expense0.00.00.00.00.00.00.00.00.10.10.1
Pre-tax income21.127.227.113.16.131.513.518.518.618.919.6
Tax rate62%31%31%78%-8%32%82%31%23%40%40%
Net income8.418.818.52.86.521.52.512.814.211.310.7
Net margin18%34%35%5%15%45%6%30%36%26%22%
Diluted EPS$0.09$0.20$0.20$0.03$0.05$0.21$0.02$0.12$0.14$0.11$0.10
Operating cash flown/a3.719.25.0-7.31.9-8.3-20.952.09.222.5
Capital expendituren/a0.70.90.40.60.30.30.00.80.10.1
Free cash flown/a3.018.34.6-7.91.7-8.6-20.951.29.122.4
Buybacksn/an/an/an/an/an/an/a2.6n/an/an/a
Shares outstanding103m104m104m103m103m104m103m103m103m103m103m
Filing10-Q10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 June 2026, filed 13 August 2026: the filing.